Silybum marianum: Beyond Hepatoprotection

Journal of Evidence-Based Complementary and Alternative Medicine

Volumn 20, Issue 4, 2015, Pages 292-301

  Bahmani, Mahmood ^a   Shirzad, Hedayatollah ^b   Rafieian, Samira ^c   Rafieian Kopaei, Mahmoud ^b  

^a URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

antioxidant; hepatoprotective remedy; Silybum marianum; Silymarin

Indexed keywords

PLANT EXTRACT; PROTECTIVE AGENT; SILYMARIN;

ANIMAL; CHEMISTRY; DRUG EFFECTS; HUMAN; IMMUNOLOGY; LIVER; LIVER DISEASES; METABOLISM; PHYTOTHERAPY;

ANIMALS; HUMANS; LIVER; LIVER DISEASES; PHYTOTHERAPY; PLANT EXTRACTS; PROTECTIVE AGENTS; SILYMARIN;

EID: 84925948278     PISSN: 21565872     EISSN: None     Source Type: Journal    
DOI: 10.1177/2156587215571116     Document Type: Article

References (111)

1. R.D.E.SewellM.Rafieian-Kopaei. The history and ups and downs of herbal medicine usage. J HerbMed Pharmacol. 2014;3(1):1–3.
2. Natural Medicines Comprehensive Database. Milk thistle monograph. Stockton, CA: Therapeutic Research Faculty. http://naturaldatabase.therapeuticresearch.com. Published 2012. Accessed November 12, 2012.
3. R.JayarajU.DebA.S.BhaskarG.B.PrasadP.V.Rao. Hepatoprotective efficacy of certain flavonoids against microcystin induced toxicity in mice. Environ Toxicol. 2007;22:472–479.
4. C.H.WuS.M.HuangG.C.Yen. Silymarin: a novel antioxidant with antiglycation and antiinflammatory properties in vitro and in vivo. Antioxid Redox Signal. 2011;14:353–366.
5. T.BrodniewiczG.Grynkiewicz. Plant phenolics as drug leads—what is missing?Acta Pol Pharm. 2012;69:1203–1217.
6. M.Rafieian-KopaieH.Nasri. Silymarin and diabetic neuropathy. J Renal Inj Prev. 2012;1(1):3–6.
7. V.ŠimánekV.KřenJ.UlrichováJ.VičarL.Cvak. Silymarin: what is in the name?Hepatology. 2000;32:442–443.
8. D.J.KrollH.S.ShawN.H.Oberlies. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther. 2007;6:110–119.
9. L.BraunM.Cohen. Herbs & Natural Supplements: An Evidence-Based Guide. 3rd ed. London, England: Churchill Livingstone; 2010.
10. N.MurataK.MurakamiY.Ozawa. Silymarin attenuated the amyloid β plaque burden and improved behavioral abnormalities in an Alzheimer’s disease mouse model. Biosci Biotechnol Biochem. 2010;74:2299–2306.
11. P.LuT.MamiyaL.L.Lu. Silibinin prevents amyloid β peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol. 2009;157:1270–1277.
12. Z.YangL.ZhuangY.LuQ.XuX.Chen. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. Biomed Res Int. 2014;2014:941085. doi:10.1155/2014/941085.
13. F.YinJ.LiuX.JiY.WangJ.ZidichouskiJ.Zhang. Silibinin: a novel inhibitor of Aβ aggregation. Neurochem Int. 2011;58:399–403.
14. P.MurielM.Mourelle. Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J Appl Toxicol. 1990;10:275–279.
15. E.HeidarianM.Rafieian-Kopaei. Effect of silymarin on liver phoshpatidate phosphohydrolase in hyperlipidemic rats. Biosci Res. 2012;9(2):59–67.
16. P.LettéronG.LabbeC.Degott. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Biochem Pharmacol. 1990;39:2027–2034.
17. G.RamakrishnanC.M.Elinos-BáezS.Jagan. Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma. Mol Cell Biochem. 2008;313:53–61.
18. A.DesplacesJ.ChoppinG.VogelW.Trost. The effects of silymarin on experimental phalloidine poisoning. Arzneimittelforschung. 1975;25:89–96.
19. P.MurielT.GarciapinaV.Perez-AlvarezM.Mourelle. Silymarin protects against liver damage. J Appl Toxicol. 1992;12:439–442.
20. M.WangL.LaGrangeJ.TaoE.Reyes. Hepatoprotective properties of Silybum marianum herbal prepararion on ethanol-induced liver damage. Fitoterapia. 1996;67:166–171.
21. A.ValenzuelaC.LagosK.SchmidtL.A.Videla. Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat. Biochem Pharmacol. 1985;34:2209–2212.
22. H.NasriN.SahinfardM.RafieianS.RafieianM.ShirzadM.Rafieian-Kopaei. Effects of Allium sativum on liver enzymes and atherosclerotic risk factors. J HerbMed Pharmacol. 2013;2(2):23–28.
23. European Scientific Cooperative on Phytotherapy. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products. 2nd editionsupplement. New York, NY: Thieme; 2009:222–248.
24. H.A.SalmiS.Sarna. Effects of silymarin on chemical, functional, and morphological alterations of the liver: a double-blind controlled study. Scand J Gastroenterol. 1982;17:517–521.
25. N.SkottovaV.Kreeman. Silymarin as a potential hypocholesterolaemic drug. Physiol Res. 1998;47:1–7.
26. J.FeherG.DeakG.Muzes. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil. 1989;130:2723–2727.
27. L.BendaH.DittrichP.FerenziH.FrankF.Wewalka. The influence of therapy with silymarin on the survival rate of patients with liver cirrhosis. Wien Klin Wochenschr. 1980;92:678–683.
28. D.BunoutS.HirschM.Petermann. Controlled study of the effect of silymarin on alcoholic liver disease. Rev Med Chil. 1992;120:1370–1375.
29. F.LirussiL.Okolicsany. Cytoprotevtion in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease. Acta Physiol Hung. 1992;80:363–367.
30. D.PlattB.Schnorr. Biochemische und elektronenoptische untersuchungen zur frage der beeinflussbarkeit der aethanolschadigung der rattenleber durch silymarin. Arzneimittelforschung. 1971;21:1206–1208.
31. H.SchriewerF.Weinhold. The influence of silybin from Silybum marianum (L.) Gaertn. on in vitro phosphatidyl choline biosynthesis in rat livers. Arzneimittelforschung. 1973;29:791–792.
32. N.KabiriM.Ahangar-DarabiM.SetorkiM.Rafieian-Kopaei. The effect of silymarin on liver injury induced by thioacetamide in rats. J HerbMed Pharmacol. 2013;2(2):29–33.
33. E.MagliuoB.GagliardiG.P.Fiori. Results of a double in the treatment of acute viral hepatitis, carried out at two medical centres. Med Klin. 1978;73:1060–1065.
34. J.C.BodeU.SchmidtH.K.Durr. Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial. Med Klin. 1977;72:513–518.
35. J.SonnenbichlerI.Zetl. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. In: V.CodyE.MiddletonJ.B.Harborne, eds. Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological and Structure-Activity Relationship. New York, NY: Alan R Liss; 1986:319–331.
36. W.Baer-DubowskaH.SzaferV.Krajkakuzniak. Inhibition of murine hepatic cytochrome P450 activities by natural and synthetic phenolic compounds. Xenobiotica. 1998;28:735–743.
37. P.MurielM.Mourelle. The role of membrane composition in ATPase activities of cirrhotic rat liver: effect of silymarin. J Appl Toxicol. 1990;10:281–284.
38. L.A.VidelaA.Valenzuela. Alcohol ingestion, liver glutathione and lipoperoxidation: metabolic interrelations and pathological implications. Life Sci. 1982;31:2395–2407.
39. H.NasriM.Rafieian-Kopaei. Herbal medicine and diabetic kidney disease. J Nephropharmacol. 2013;2(1):1–2.
40. N.SkottovaV.Krecman. Dietary silymarin improves removal of low density lipoproteins by the perfused rat liver. Acta Univ Palacki Olomuv Fac Med. 1998;141:39–40.
41. G.NassuatoR.M.IemmoloM.Strazzabosco. Effect of silibinin on biliary lipid composition experimental and clinical study. J Hepatol. 1992;12:290–295.
42. A.SomogyiG.G.EcsediA.BlazovicsK.MiskolcziP.GergelyJ.Feher. Short term treatment of type II hyperlipoproteinaemia with silymarin. Acta Med Hung. 1989;46:289–295.
43. T.ZimaL.KamenikovaM.JanebovaE.BucharT.CrkovskaV.Tesar. The effects of silibinin on experimental cyclosporine nephrotoxicity. Ren Fail. 1998;20:471–479.
44. S.J.BrantleyN.H.OberliesD.J.KrollM.F.Paine. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther. 2010;332:1081–1087.
45. G.VessalM.AkmaliP.NajafiM.R.MoeinM.M.Sagheb. Silymarin and milk thistle extract may prevent the progression of diabetic nephropathy in streptozotocin-induced diabetic rats. Ren Fail. 2010;32:733–739.
46. C.SotoJ.PérezV.GarcíaE.UríaM.VadilloL.Raya. Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus. Phytomedicine. 2010;17:1090–1094.
47. C.M.MeyersJ.P.Briggs. Silymarin for diabetic nephropathy: the challenges of botanical product research. Am J Kidney Dis. 2012;60:887–889.
48. M.K.FallahzadehB.DormaneshM.M.Sagheb. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis. 2012;60:896–903.
49. M.J.WangW.W.LinH.L.Chen. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglial activation. Eur J Neurosci. 2002;16:2103–2112.
50. J.Q.ZangX.M.MaoY.P.Zhon. Effects of silybin on red blood cell sorbitol and nerve conduction velocity in diabetic patients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1993;13:725–726.
51. M.RoghaniM.KhaliliT.BaluchnejadmojaradM.Ahmadi. Protective effect of silymarin on learning and memory deficiency in streptozotocin-diabetic rats. J Gorgan Univ Med Sci. 2013;15:35–41.
52. C.P.SotoB.L.PerezL.P.FavariJ.L.Reyes. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998;119:125–129.
53. C.G.ZouN.S.AgarG.L.Jones. Oxidative insult to human red blood cells induced by free radical initiator AAPH and its inhibition by a commercial antioxidant mixture. Life Sci. 2001;69:75–86.
54. I.LangK.NekamR.Gonzalez-CabelloG.MuzesP.GergelyJ.Feher. Hepatoprotective and immunological effects of antioxidant drugs. Tokai J Exp Clin Med. 1990;15:123–127.
55. X.ZiH.MukhtarR.Agarwal. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun. 1997;239:334–339.
56. M.Rafieian-KopaeiA.BaradaranM.Rafieian. Oxidative stress and the paradoxical effects of antioxidants. J Res Med Sci. 2013;18:629.
57. G.ScambiaR.De VincenzoF.O.Ranellletti. Antiprolifeative effect of silybin on gunaecological malignancies: synergism with cisplatin and doxorubicin. Eur J Cancer. 1996;32:877–882.
58. M.L.ChatterjeeR.AgarwalH.Mukhtar. Ultraviolet B radiation-induced DNA lesions in mouse epidermis: an assessment using a novel 32P-posylabelling technique. Biomed Biophys Res Commun. 1996;229:590–595.
59. J.SonnenbichlerM.GoldbergL.HaneI.MadubunyiS.VoglI.Zetl. Stimulatory effects of silibin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malignant cell lines. Biochem Pharmacol. 1986;35:538–541.
60. H.NasriM.Rafieian-Kopaei. Medicinal plants and antioxidants: why they are not always beneficial?Iranian J Public Health. 2014;43:255–257.
61. H.P.KochJ.BachnerE.Loffler. Silymarin: potent inhibitor of cyclic AMP phosphodiester. Methods Find Exp Clin Pharmacol. 1985;7:409–413.
62. Adverse Reactions Advisory Committee. An adverse reaction to the herbal medication milk thistle (Silybum marianum). Med J Aust. 1999;170:218–219.
63. M.BahmaniA.ZargaranM.Rafieian-Kopaei. Identification of medicinal plants of Urmia for treatment of gastrointestinal disorders. Rev Bras Farmacogna. 2014;24:468–480.
64. N.Kafash-FarkhadM.Asadi-SamaniM.Rafieian-Kopaei. A review on phytochemistry and pharmacological effects of Prangos ferulacea (L.) Lindl. Life Sci J. 2013;10(8 suppl):360–367.
65. A.BaradaranH.NasriM.Rafieian-Kopaei. Oxidative stress and hypertension: possibility of hypertension therapy with antioxidants. J Res Med Sci. 2014;19:358–367.
66. H.NasriM.Rafieian-Kopaei. Protective effects of herbal antioxidants on diabetic kidney disease. J Res Med Sci. 2014;19:82–83.
67. A.BaradaranM.Rafieian-Kopaei. Re: Protective role of silymarin and deferoxamine against iron dextran-induced renal iron deposition in male rats. Int J Prev Med. 2014;5:245–246.
68. P.SchleufeC.Seidel. Amanita poisoning during pregnancy. Anasthesiol Intensivmed Notfallmed Schmerzther. 2003;38:716–718.
69. G.RahimianM.H.SaneiH.Shirzad. Virulence factors of Helicobacter pylori vacA increase markedly gastric mucosal TGF-β1 mRNA expression in gastritis patients. Microb Pathog. 2014;67-68:1–7.
70. S.G.Ottariano. Medicinal Herbal Therapy: A Pharmacist’s View. Portsmouth, NH: Nicoln Fields; 1999.
71. F.FraschiniG.DemartiniD.Esposti. Pharmacology of Silymarin. Clin Drug Invest. 2002;22(1):1–7.
72. M.Becker-ScheibeM.MengsM.SchaeferM.BulittaW.Hoffman. Topical use of a silymarin-based preparation to prevent radiodermatitis: results of a prospective study in breast cancer patients. Strahlenther Onkol. 2011;187:485–491.
73. Z.RabieiM.Rafieian-KopaeiE.HeidarianE.SaghaeiS.Mokhtari. Effects of Zizyphus jujube extract on memory and learning impairment induced by bilateral electric lesions of the nucleus Basalis of Meynert in rat. Neurochem Res. 2014;39:353–360.
74. A.BaradaranZ.RabieiM.RafieianH.Shirzad. A review study on medicinal plants affecting amnesia through cholinergic system. J HerbMed Plarmacol. 2012;1(1):3–9.
75. M.Rafieian-KopaeiA.M.GrayP.S.SpencerR.D.Sewell. Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioning. Eur J Pharmacol. 1995;275:185–189.
76. H.RoohafzaN.SarrafzadeganM.SadeghiM.Rafieian-KopaeiF.SajjadiH.Khosravi-Boroujeni. The association between stress levels and food consumption among Iranian population. Arch Iran Med. 2013;16:145–148.
77. A.BaradaranY.MadihiA.MerrikhiM.Rafieian-KopaeiH.Nasri. Serum lipoprotein (a) in diabetic patients with various renal function not yet on dialysis. Pak J Med Sci. 2013;29(1 suppl):354–357.
78. S.BehradmaneshM.K.HorestaniA.BaradaranH.Nasri. Association of serum uric acid with proteinuria in type 2 diabetic patients. J Res Med Sci. 2013;18:44–46.
79. Y.MadihiA.MerrikhiA.Baradaran. Bioactive components and the effect of hydroalcoholic extract of Vaccinium myrtillus on postprandial atherosclerosis risk factors in rabbits. Pak J Med Sci. 2013;29(1 suppl):384–389.
80. M.SetorkiB.NazariS.AsgaryL.AzadbakhtM.Rafieian-Kopaei. Antiatherosclerotic effects of verjuice on hypocholesterolemic rabbits. Afr J Pharm Pharmacol. 2011;5:1038–1045.
81. H.Khosravi-BoroujeniN.SarrafzadeganN.Mohammadifard. White rice consumption and CVD risk factors among Iranian population. J Health Popul Nutr. 2013;31:252–261.
82. M.SadeghiH.Khosravi-BoroujeniN.Sarrafzadegan. Cheese consumption in relation to cardiovascular risk factors among Iranian adults—IHHP study. Nutr Res Pract. 2014;8:336–341.
83. H.ShirzadM.ShahraniM.Rafieian-Kopaei. Comparison of morphine and tramadol effects on phagocytic activity of mice peritoneal phagocytes in vivo. Int Immunopharmacol. 2009;9:968–970.
84. H.ShirzadF.TajiM.Rafieian-Kopaei. Correlation between antioxidant activity of garlic extracts and WEHI-164 fibrosarcoma tumor growth in BALB/c mice. J Med Food. 2011;14:969–974.
85. M.A.KianiA.KhodadadS.Mohammadi. Effect of peppermint on pediatrics’ pain under endoscopic examination of the large bowel. J HerbMed Pharmacol. 2013;2(2):41–44.
86. N.BagheriA.TaghikhaniG.Rahimian. Association between virulence factors of Helicobacter pylori and gastric mucosal interleukin-18 mRNA expression in dyspeptic patients. Microb Pathog. 2013;65:7–13.
87. M.Rafiean-KopaeiA.BaradaranA.R.MaghsoudiS.H.GhobadiH.Nasri. Helicobacter pylori infection and serum homocysteine in hemodialysis patient. Life Sci J. 2012;9:3696–3702.
88. N.BagheriG.H.RahimianL.Salimzadeh. Association of the virulence factors of Helicobacter pylori and gastric mucosal interleukin-17/23 mRNA expression in dyspeptic patients. EXCLI J. 2013;12:5–14.
89. S.Y.AsadiP.ParsaeiM.Karimi. Effect of green tea (Camellia sinensis) extract on healing process of surgical wounds in rat. Int J Surg. 2013;11:332–337. doi:10.1016/j.ijsu.2013.02.014.
90. P.ParsaeiM.KarimiS.Y.AsadiM.Rafieian-Kopaei. Bioactive components and preventive effect of green tea (Camellia sinensis) extract on postlaparotomy intra-abdominal adhesion in rats. Int J Surg. 2013;11:811–815. doi:10.1016/j.ijsu.2013.08.014.
91. H.NasriM.Rafieian-Kopaei. Tubular kidney protection by antioxidants. Iranian J Public Health. 2013;42:1194–1196.
92. A.BaradaranH.NasriM.NematbakhshM.Rafieian-Kopaei. Antioxidant activity and preventive effect of aqueous leaf extract of Aloe Vera on gentamicin-induced nephrotoxicity in male Wistar rats. Clin Ter. 2014;165:7–11.
93. H.NasriM.TavakoliA.AhmadiA.BaradaranM.NematbakhshM.Rafieian-Kopaei. Ameliorative effect of melatonin against contrast media induced renal tubular cell injury. Pak J Med Sci. 2014;30:261–265.
94. M.Rafieian-KopaeiH.Nasri. The ameliorative effect of Zingiber officinale in diabetic nephropathy. Iran Red Crescent Med J. 2014;16:e11324.
95. M.Rafieian-KopaeiN.ShahinfardH.Rouhi-BoroujeniM.GharipourP.Darvishzadeh-Boroujeni. Effects of Ferulago angulata extract on serum lipids and lipid peroxidation. Evid Based Complement Alternat Med. 2014;2014:680856. doi:10.1155/2014/680856.
96. S.AsgaryA.SahebkarM.R.AfshaniM.KeshvariS.HaghjooyjavanmardM.Rafieian-Kopaei. Clinical evaluation of blood pressure lowering, endothelial function improving, hypolipidemic and anti-inflammatory effects of pomegranate juice in hypertensive subjects. Phytother Res. 2013;28:193–199. doi:10.1002/ptr.4977.
97. S.RahnamaZ.RabieiZ.AlibabaeiS.MokhtariM.Rafieian-kopaeiF.Deris. Anti-amnesic activity of Citrus aurantium flowers extract against scopolamine-induced memory impairments in rats. Neurol Sci. 2014:1–8.
98. R.SharafatiF.SharafatiM.Rafieian-Kopaei. Biological characterization of Iranian walnut (Juglans regia) leaves. Turk J Biol. 2011;35:635–639.
99. H.NasriA.BaradaranM.R.ArdalanS.MardaniA.MomeniM.Rafieian-Kopaei. Bright renoprotective properties of metformin: beyond blood glucose regulatory effects. Iran J Kidney Dis. 2013;7:423–428.
100. M.Rafieian-KopaeiS.BehradmaneshS.KheiriH.Nasri. Association of serum uric acid with level of blood pressure in type 2 diabetic patients. Iran J Kidney Dis. 2014;8:152–154.
101. M.TaghikhaniH.NasriA.Asgari. The renal toxicity of hydroalcoholic extract of Stachys lavandulifolia Vahl in Wistar rats. Life Sci J. 2012;9:3025–3031.
102. M.BahmaniM.Rafieian-Kopaei. Medicinal plants and secondary metabolites for leech control. Asian Pac J Trop Dis. 2014;4:315–316.
103. M.AmirmohammadiS.KhajoeniaM.BahmaniM.Rafieian-KopaeiZ.EftekhariM.Qorbani. In vivo evaluation of antiparasitic effects of Artemisia abrotanum and Salvia officinalis extracts on Syphacia obvelata, Aspiculoris tetrapetra and Hymenolepis nana parasites. Asian Pac J Trop Dis. 2014;4(suppl 1):250–254.
104. M.BahmaniA.ZargaranM.Rafieian-KopaeiM.Saki. Ethnobotanical study of medicinal plants used in the management of diabetes mellitus in the Urmia, Northwest Iran. Asian Pac J Trop Med. 2014;7(suppl 1):348–354.
105. K.Hosseini-AslM.Rafieian-Kopaei. Can patients with active duodenal ulcer fast Ramadan?Am J Gastroenterol. 2002;97:2471–2472.
106. A.TaghikhaniH.AfroughR.Ansari-SamaniN.ShahinfardM.Rafieian-Kopaei. Assessing the toxic effects of hydroalcoholic extract of Stachys lavandulifolia Vahl on rat’s liver. Bratisl Lek Listy. 2014;115:121–124.
107. E.HeidarianM.Rafieian-Kopaei. Protective effect of artichoke (Cynara scolymus) leaf extract against lead toxicity in rat. Pharm Biol. 2013;51:1104–1109.
108. A.BaradaranH.NasriM.Rafieian-Kopaei. Comment on: Anti-oxidative stress activity of Stachys lavandulifolia aqueous extract in humans. Cell J. 2013;15:272–273.
109. A.BaradaranY.MadihiA.Merrikhi. Nephrotoxicity of hydroalcoholic extract of Teucrium polium in Wistar rats. Pak J Med Sci. 2013;29(1 suppl):329–333.
110. F.GhaedM.Rafieian-KopaeiA.BaradaranH.Nasri. Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats. J Res Med Sci. 2012;17:621–625.
111. W.N.JeffersonG.Padiilla-BanksR.R.Newbold. Assessing estrogenic activity of phytochemicals using transcriptional activation and immature mouse uterotrophic responses. J Chromatogr. 2002;777:179–189.